ClinicalTrials.gg
CompletedNCT07322991Updated Jan 7, 2026

Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects.

A Phase 1 interventional study of IY001(Finasteride) and IY002(Tamsulosin) in Healthy Adult Male, sponsored by Il-Yang Pharm. Co., Ltd.. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this stud is to evaluate the drug-drug interaction between IY001 and IY002 in adult males.

Read the detailed description

The study is an Open-label, Phase I, drug-drug interaction study.

02

Conditions studied

  • Healthy Adult Male

Keywords

  • Urology
  • Drug-Drug Interaction
03

In context

Lead sponsor

Il-Yang Pharm. Co., Ltd. is the lead sponsor of 34 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged between 19 and 55 years at screening.
  • Body weight ≥ 50 kg and (BMI) between 18 and 30 kg/m² (BMI calculated as weight [kg] / height [m]²).
  • No congenital or chronic diseases, and no pathological signs or symptoms based on internal medicine examination (including EEG, , chest or upper gastrointestinal endoscopy, or gastrointestinal radiographic examination, if necessary).
  • Considered suitable for participation by the principal investigator (or delegated sub-investigator) based on diagnostic tests such as hematology, blood chemistry, serology, urinalysis, ECG, suicide risk assessment, and depression scale evaluation conducted in accordance with the characteristics of the drugs.
  • Able to provide written after receiving a detailed explanation of the clinical trial and voluntarily agreeing to participate and comply with study requirements during the trial period.
  • Agree to use highly effective * (excluding hormonal methods) and refrain from donating sperm from the first dose until at least 4 weeks after the last dose of the investigational drugs. This includes agreement that the subject or their partner will avoid pregnancy.

    *Highly effective contraception methods include: intrauterine device (IUD), bilateral tubal ligation, vasectomy of partner, or sexual abstinence. Methods such as periodic abstinence (calendar method, basal body temperature, ovulation method), withdrawal, use of spermicides alone, lactational amenorrhea, or simultaneous use of male and female condoms are not considered effective contraception.

  • Agree not to donate blood from the first dose until at least 4 weeks after the last dose of the investigational drugs.

Exclusion criteria

Exclusion Criteria:

  • Use of drug-metabolizing enzyme inducers or inhibitors (e.g., barbiturates) within 30 days prior to the first dose, or use of such medications within 10 days prior to the first dose.
  • Participation in a bioequivalence study or other clinical trial involving drugs within 6 months prior to the first dose.
  • Whole blood donation within 8 weeks, plasma donation within 2 weeks, or blood transfusion within 4 weeks prior to the first dose.
  • History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia surgery).
  • Within 1 month prior to the first dose:

    • Average alcohol consumption exceeding 21 drinks per week (1 drink = 50 mL soju, 250 mL beer, or 30 mL spirits)
    • Smoking more than 20 cigarettes per day
  • Any of the following conditions:

    • History of (including angioedema) to the investigational drug or its components
    • Orthostatic hypotension
    • Severe hepatic impairment
    • Severe renal impairment
    • Currently taking PDE5 inhibitors
    • Currently taking inhibitors
    • Currently taking antihypertensive drugs
    • Currently taking alpha-1 blockers
    • History of micturition syncope
    • Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
    • Hypersensitivity or allergy to Sunset Yellow FCF (Yellow No. 5) contained in the drug
  • History of psychiatric disorders.
  • Any other condition that the principal investigator (or delegated sub-investigator) deems makes the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Part A

    IY001 -\> IY001 + IY002

    Drug: IY001(Finasteride) · Drug: IY002(Tamsulosin)

  • Experimental
    Part B

    IY002 -\> IY001 + IY002

    Drug: IY001(Finasteride) · Drug: IY002(Tamsulosin)

Interventions

  • Subjects will receive IY001 once daily for 3 days, followed by co-administration of IY001 and IY002 once daily for 5 days.

  • Subjects will receive IY002 once daily for 5 days, followed by co-administration of IY001 and IY002 once daily for 3 days.

06

What researchers measure

Primary outcomes

  1. Finasteride Area Under the Curve during the dosing interval at steady state (AUCτ,ss)

    The total drug exposure of finasteride over the dosing interval at steady state.

    Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 3)

  2. Finasteride Maximum Plasma Concentration at steady state (Cmax,ss)

    The peak plasma concentration of finasteride observed at steady state.

    Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 3)

  3. Tamsulosin Area Under the Curve during the dosing interval at steady state (AUCτ,ss)

    The total drug exposure of tamsulosin over the dosing interval at steady state.

    Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 5)

  4. Tamsulosin Maximum Plasma Concentration at steady state (Cmax,ss)

    The peak plasma concentration of tamsulosin observed at steady state.

    Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 5)

Secondary outcomes

  1. Finasteride Time to Maximum Plasma Concentration at steady state (Tmax,ss)

    Time to reach the maximum plasma concentration of finasteride measured from plasma samples collected at pre-dose and multiple post-dose time points on Days 3 and 8.

    Time frame: Days 3 and 8

  2. Finasteride Elimination Half-Life at Steady State (t1/2,ss)

    The elimination half-life of finasteride calculated using plasma concentrations from serial blood samples collected up to 24 hours post-dose on Days 3 and 8.

    Time frame: Days 3 and 8

  3. Finasteride Apparent Clearance at Steady State (CLss/F)

    Apparent clearance of finasteride derived from plasma concentration-time data obtained from serial blood sampling on Days 3 and 8.

    Time frame: Days 3 and 8

  4. Finasteride Minimum Plasma Concentration at Steady State (Cmin,ss)

    Minimum plasma concentration measured from pre-dose (0 hour) samples collected on Days 1, 2, 7, and 8.

    Time frame: Days 1, 2, 7, and 8

  5. Finasteride Average Plasma Concentration at Steady State (Cav,ss)

    Average plasma concentration calculated over the dosing interval from serial samples collected on Days 3 and 8.

    Time frame: Days 3 and 8

  6. Finasteride Accumulation Ratio (R)

    Ratio of plasma concentrations comparing steady state (Day 8) to earlier dosing period (Day 3).

    Time frame: Days 3 and 8

  7. Finasteride Peak-Trough Fluctuation (PTF)

    Fluctuation between peak (Cmax) and trough (Cmin) plasma concentrations calculated from serial sampling on Days 3 and 8.

    Time frame: Days 3 and 8

  8. Tamsulosin Time to Maximum Plasma Concentration at Steady State (Tmax,ss)

    Time to reach the maximum plasma concentration of tamsulosin measured from plasma samples collected at pre-dose and multiple post-dose time points on Days 5 and 8.

    Time frame: Days 5 and 8

  9. Tamsulosin Elimination Half-Life at Steady State (t1/2,ss)

    Elimination half-life calculated from plasma concentrations obtained up to 24 hours post-dose on Days 5 and 8.

    Time frame: Days 5 and 8

  10. Tamsulosin Apparent Clearance at Steady State (CLss/F)

    Apparent clearance derived from plasma concentration-time data on Days 5 and 8.

    Time frame: Days 5 and 8

  11. Tamsulosin Minimum Plasma Concentration at Steady State (Cmin,ss)

    Minimum plasma concentration measured from pre-dose samples collected on Days 1, 4, 7, and 8.

    Time frame: Days 1, 4, 7, and 8

  12. Tamsulosin Average Plasma Concentration at Steady State (Cav,ss)

    Average plasma concentration over dosing interval calculated from serial samples on Days 5 and 8.

    Time frame: Days 5 and 8

  13. Tamsulosin Accumulation Ratio (R)

    Ratio of plasma concentrations comparing steady state (Day 8) to earlier dosing period (Day 5).

    Time frame: Days 5 and 8

  14. Tamsulosin Peak-Trough Fluctuation (PTF)

    Fluctuation between peak (Cmax) and trough (Cmin) plasma concentrations from serial sampling on Days 5 and 8.

    Time frame: Days 5 and 8

07

Study locations

1 site
  • H plus Yangji Hospital
    Seoul, Seoul 08779, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 7, 2026
StartActual
Oct 14, 2025
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07322991
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Oct 14, 2025
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
Jan 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finasteride · Tamsulosin

Start the discussion